| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 07/14/2005 | US20050154025 6-[4-(fluoro- or trifluoromethyl)pyridyl-4-(p-fluorophenyl)-5-methylimidazol-2-yl] pyridones; cyclization of 1-phenyl-1-pyridyl-1,2-diaminopropanes with an acid, amidine, or nitrile compound; neuropeptide Y receptor antagonists; cardiovascular and central nervous system disorders, metabolic diseases |
| 07/14/2005 | US20050154019 Substituted cyclic amine metalloprotease inhibitors |
| 07/14/2005 | US20050153993 Treatment of statin side effects using uridine derivatives |
| 07/14/2005 | US20050153960 Substituted arylamine derivatives and methods of use |
| 07/14/2005 | US20050153941 Cell differntiation inhibiting agent, cell culture method using the same, culture medium, and cultured cell line |
| 07/14/2005 | US20050153917 Gene overexpression/underexpression; antibodies; drug screening; kits |
| 07/14/2005 | US20050153902 Inhibitors of integrin avb6 |
| 07/14/2005 | US20050153889 Modulation of pericyte proliferation |
| 07/14/2005 | US20050152926 For immunization and/or diagnosis; eg pneumonia, cardiovascular diseases, atherosclerosis, bronchitis |
| 07/14/2005 | CA2548146A1 Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration |
| 07/14/2005 | CA2548035A1 Cdk2 antagonists as short form c-maf transcription factor antagonists for treatment of glaucoma |
| 07/14/2005 | CA2547852A1 Agents for treatment of glaucomatous retinopathy and optic neuropathy |
| 07/13/2005 | EP1553098A1 Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient |
| 07/13/2005 | EP1553097A1 Quinazoline derivatives as angiogenesis inhibitors and intermediates therefore |
| 07/13/2005 | EP1552842A1 Bicyclic pyrimidine derivatives |
| 07/13/2005 | EP1552838A1 Rubrofusarin glycoside-containing composition |
| 07/13/2005 | EP1552830A1 Drug composition for prevention or inhibition of advance of diabetic complication |
| 07/13/2005 | EP1551865A2 Hybrid molcules of macrolides with steroid/non-steroid anti-inflammatory, antineoplastic and antiviral active molecules |
| 07/13/2005 | EP1551837A1 Phosphodiesterase 4 inhibitors |
| 07/13/2005 | EP1551793A1 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same |
| 07/13/2005 | EP1551433A1 Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease |
| 07/13/2005 | EP1551417A2 Three layer tear formulation |
| 07/13/2005 | EP1551416A2 Method for treating erectile dysfunction and increasing libido in men |
| 07/13/2005 | EP1551412A1 Pharmaceutical compositions for the treatment of diseases related to neurotrophines |
| 07/13/2005 | EP1551381A2 Styrylacrylonitrile compounds for inhibition of vascular endothelial growth factor |
| 07/13/2005 | EP1235802B1 Carbamate derivatives having muscarinic receptor antagonist activity |
| 07/13/2005 | EP1161415B1 N-cyanomethylamides as protease inhibitors |
| 07/13/2005 | EP1113795B1 Tryptophanyl esters and their n-acyl derivatives for the prevention and treatment of diseases caused or exacerbated by oxidation processes |
| 07/13/2005 | CN1639188A Hepta-, octa- and nonapeptides having antiangiogenic activity |
| 07/13/2005 | CN1639161A Alkyne-aryl phosphodiesterase-4 inhibitors |
| 07/13/2005 | CN1639148A 喹啉衍生物 Quinoline derivatives |
| 07/13/2005 | CN1639126A Nitrosodiphenylamine derivatives and their pharmaceutical use against oxidative stress pathologies |
| 07/13/2005 | CN1639125A New inhibitors of histone deacetylase |
| 07/13/2005 | CN1639119A Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors |
| 07/13/2005 | CN1638796A Methods of administering anti-TNF alpha antibodies |
| 07/13/2005 | CN1638789A Methods of treating disorders of the eye and surrounding tissue with thymosin beta4 (t beta 4), analogues, isoforms and other derivatives |
| 07/13/2005 | CN1638769A Ophthalmic composition comprising ascomycin |
| 07/13/2005 | CN1638764A Eye drops containing tetrazole derivative |
| 07/13/2005 | CN1638762A Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists |
| 07/13/2005 | CN1638760A Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 07/13/2005 | CN1638739A Compound for treating assuetude disturbance |
| 07/13/2005 | CN1638734A Drug delivery system for the subconjunctival administration of fine grains |
| 07/13/2005 | CN1638650A Composition improving age-related physiological deficits and increasing longevity |
| 07/13/2005 | CN1636994A Process of preparing alkali metal salys of hydrophobic sulfonamides and alkali metal salt produced thereby |
| 07/13/2005 | CN1636983A Substituted heterocyclic compounds |
| 07/13/2005 | CN1636977A 1, 3-disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists |
| 07/13/2005 | CN1636594A Angiostatin and use of the same for inhibition of angiogenesis |
| 07/13/2005 | CN1636590A Pharmaceutical preparation containing cyclopeptide and chemotherapeutic agent or angiogenesis inhibitor |
| 07/13/2005 | CN1636568A Eye drop of tobramycin and sodium hyaluronate and its prepn process |
| 07/13/2005 | CN1210270C Novel use of phenylheteroalkylamine derivatives |
| 07/13/2005 | CN1210028C Aqueous liquid preparation |
| 07/12/2005 | US6917616 Method and apparatus for reduction and restoration of data elements pertaining to transmitted data packets in a communications network |
| 07/12/2005 | US6916958 Aminobiguanides and the use thereof to disinfect contact lenses and preserve pharmaceutical compositions |
| 07/12/2005 | US6916927 Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction |
| 07/12/2005 | US6916848 Compounds for the treatment of metabolic disorders |
| 07/12/2005 | US6916838 1-benzylpyrazole-3-carboxylic acid tricyclic derivatives as cannabinoid receptor antagonists |
| 07/12/2005 | US6916828 Irritiable bowel syndrome; respiartory system disorders; antihistamines; gastrointestinal disorders |
| 07/12/2005 | US6916814 Methods of treating cytokine mediated diseases |
| 07/12/2005 | US6916810 αν integrin receptor antagonists |
| 07/12/2005 | US6916807 Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 07/12/2005 | US6916804 Pyrimidine A2b selective antagonist compounds, their synthesis and use |
| 07/12/2005 | US6916794 Method of enhancing drainage of lacrimal system with purinergic receptor agonists |
| 07/12/2005 | CA2341739C Quinolin-2-one derivatives useful as anticancer agents |
| 07/12/2005 | CA2230947C Implantable controlled release device to deliver drugs directly to an internal portion of the body |
| 07/12/2005 | CA2160798C Gaba-ergic modulation of eye growth |
| 07/07/2005 | WO2005061492A1 Nitrogen-containing heterocyclic compounds and drugs comprising the same as the active ingredient |
| 07/07/2005 | WO2005009954A3 Method for modulating calcium ion-release-activated calcium ion channels |
| 07/07/2005 | WO2003089583A3 Tissue specific genes and gene clusters |
| 07/07/2005 | US20050148672 reacting methyl bromide and 2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-(trifluoromethyl) phenol; formation of (3R)-3-[2-hydroxy-5-(trifluoromethyl)phenyl]-N,N-diisopropyl-N-methyl-3-phenylpropan-1-aminium bromide; asthma, chronic obstructive pulmonary disorder, allergic and infectious rhinitis |
| 07/07/2005 | US20050148670 Skin disorders; antiinflammatory agents; antiproliferative agents; controlling metabolism; obesity; antilipemic agents; antihistamines |
| 07/07/2005 | US20050148664 therapy of NF-kappaB mediated diseases; mitochondrial diseases; transplantation medicine |
| 07/07/2005 | US20050148636 Useful aroyl pyrrole heteroaryl methanones and methanols |
| 07/07/2005 | US20050148633 Method for modulating calcium ion-release-activated calcium ion channels |
| 07/07/2005 | US20050148619 Sulfonamido ether substituted imidazoquinolines |
| 07/07/2005 | US20050148607 Administering to show overactivation or expression from diagnosis of diseases, immunoassay, anticancer agents or skin disorders |
| 07/07/2005 | US20050148604 Increase the intracellular cAMP level and further inhibit the activation of T cells; allergic diseases, inflammatory or immunological diseases |
| 07/07/2005 | US20050148591 Tartrate salts of 5,8,14-triazatetracyclo [10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaen and pharmaceutical compositions thereof |
| 07/07/2005 | US20050148578 1H-8-oxa-1-aza-dibenzo[e,h]azulene; dual inhibitors of tumour necrosis factor(alpha) and interleukin 1; antiinflammatory, analgesics |
| 07/07/2005 | US20050148577 2-methyl-1,8-dioxa-dibenzo[e,h]azulene; potentiation; dual inhibitors of tumour necrosis factor(alpha) and interleukin 1; antiinflammatory, analgesics |
| 07/07/2005 | US20050148576 Dibenzo[b.f]oxazolo-azulines, -oxepines and -thiepines; antiinflammatories; analgesics |
| 07/07/2005 | US20050148575 (Di)Azepino[5,4,3-cd]benzothiophenes; poly(ADP-ribose) polymerase (PARP) and glycohydrolase (PARG) inhibitor; antiinflammatory; protects cells, tissue and organs against the ill-effects of reactive free radicals and nitric oxide, and damage following focal ischemia and reperfusion injury |
| 07/07/2005 | US20050148527 Catalytic nucleic acids; ribozymes; translation inhibition; gene expression inhibition; for treating cardiovascular disease; for neovascularization induction in heart tissue |
| 07/07/2005 | US20050148515 Peptidomimetics; determining ability to bind growth hormone secretagogue; ghrelin agonists; appetite stimulation; dietetics |
| 07/07/2005 | US20050148058 Protein stabilization |
| 07/07/2005 | US20050148034 Using reduced microvessel outgrowth of pluripotent stem cells as diagnostic indicator angoigenseis inhibition; antitumor agents |
| 07/07/2005 | US20050147665 Consisting of eicosapentaenoic acid or derivative, vitamin B 12, folic acid, at a maximum daily dose of 5 mg, and vitamin B6, at a maximum daily dose of 20 mg, and optionally at least one antioxidant; treatment of psychiatric disorders; schizophrenia, Alzheimer's disease, dementia, Parkinson's disease |
| 07/07/2005 | US20050147612 Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| 07/07/2005 | CA2550482A1 Vaccine comprising an angiomotin or a polynucleotide encoding an angiomotin and its uses for the treatment of angiogenic-related disorders |
| 07/07/2005 | CA2545962A1 Use of organic buffering agents to enhance the antimicrobial activity of pharmaceutical compositions |
| 07/07/2005 | CA2545947A1 Ophthalmic compositions containing a polysaccharide/borate gelling system |
| 07/07/2005 | CA2545777A1 Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents |
| 07/06/2005 | EP1550660A1 Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same |
| 07/06/2005 | EP1550448A1 Histamine release inhibitor |
| 07/06/2005 | EP1549756A2 Recombinatant mutants of rhabdovirus and methods of use thereof |
| 07/06/2005 | EP1549741A1 Novel endothelial cells, antibodies directed against said cells and use thereof, in particular for screening angiogenesis inhibiting substances |
| 07/06/2005 | EP1549660A2 RNA INTERFERENCE MEDIATED INHIBITION OF GRB2-ASSOCIATED BINDING PROTEIN 2 (GAB2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 07/06/2005 | EP1549651A1 Kinase inhibitors |
| 07/06/2005 | EP1549640A2 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
| 07/06/2005 | EP1549637A1 1- (indol-3-yl)carbonyl piperazine derivatives |
| 07/06/2005 | EP1549634A1 Novel substituted indoles |